Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since
Session topic: STEP 2 (Lancet, 2021). Please read it before posting; the discussion is much better when everyone has.
The question I would like us to start with is what the trial set out to estimate, rather than what it found. Once that is on the table we can talk about whether the design could have answered it, and only then about the numbers.
Specific things I would like covered: the population and how far it generalises, how discontinuation was handled, whether the comparator was a fair one, and what the absolute rather than relative effect looks like.
I will summarise at the end and the summary will feed the relevant digest page.